Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18‐month studies
Abstract
Demonstration of a disease‐modifying effect of a therapeutic agent on Alzheimer's disease (AD) requires a trial lasting for at least 18 months. An understanding of expected rates of adverse events (AEs), overall discontinuations, and discontinuations due to AEs, serious AEs, and deaths would be useful in planning such trials.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 05, 2011
- Source ID
- 10.1016/j.jalz.2011.05.2413
Entities
People
- David B. Henley
- Eric R. Siemers
- Gopalan Sethuraman
- Karen L. Sundell
Organizations
- Dana Foundation
- Lilly Research Laboratories
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education